 |
 |
 |
 |
 |
| March 2009 | > EXPAND ALL ARTICLES |
|
NSW Cancer Technology Keeps Tales Wagging
A new cancer treatment program using nanotechnology is reporting success in prolonging the life of some terminally ill canine companions
18 dogs with late stage cancer were treated as part of the project and reportedly experienced a rapid decrease in the burden of cancer and an improvement on their quality of life. | ||
 Read more | BACK TO TOP | 
| |
Lane Cove company EnGeneIC has created a cancer treatment called the EnGeneIC Delivery Vehicle (EDV) as part of a Department of State and Regional Development supported biotechnology project. | ||
 | ||
|
|
Polartechnics Secures Asian Contracts Following NSW Trade Mission
Minister for State Development Ian Macdonald congratulates Erskineville medical device company on $7 million distribution agreements
| ||
| Read more | BACK TO TOP |
| |
Minister for State Development Ian Macdonald recently congratulated Erskineville medical device company Polartechnics for securing distribution agreements valued at over $7 million in Thailand, Philippines, Indonesia and Sri Lanka, following its participation in a NSW trade mission.
| ||
| ||
|
|
Stem Cell Breakthrough Gives New Hope to Sufferers of Muscle-Wasting Disease
An experimental procedure that dramatically strengthens stem cells’ ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases
| ||
| Read more | BACK TO TOP |
| |
An experimental procedure that dramatically strengthens stem cells’ ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy, according to researchers from the University of New South Wales (UNSW). The world-first procedure has been successfully used to regrow muscles in a mouse model, but it could be applied to all tissue-based illnesses in humans such as in the liver, pancreas or brain, the researchers say.
| ||
| ||
|
|
Results Confirm Potential for Local Breast Cancer Test in Europe
Sydney company Fermiscan has announced the results of an independent Italian study that may lead to use of the Australian developed test throughout Europe.
| ||
| Read more | BACK TO TOP |
| |
The study was carried out under the supervision of the Centre for Oncological Prevention of the Piemonte Region, in conjunction with a major breast cancer screening program, where approximately 250,000 mammograms per year are performed in a population of 4,000,000 people.
| ||
| ||
|
|
Pharmaxis Appoints French Distributor
Pharmaxis has appointed Praxis Pharmaceutical France SARL as its French marketer and distributer for the asthma diagnostic tool, Aridol  Praxis Pharmaceutical is a recently established company created to introduce a portfolio of respiratory specialist products into the French pharmaceutical market. Praxis will complete the reimbursement application for Aridol in France and thereafter market the product to hospital specialists. | ||
| Read more | BACK TO TOP |
| |
| ||
| ||
|
|
Ventracor announces Successful Completion of VentrAssist BTT Trial
Ventracor Limited have reported that the US Bridge To Transplant (BTT) Trial of the VentrAssist® Left Ventricular Assist Device (LVAD) has reached a successful completion  The Data and Safety Monitoring Board (DSMB) met to review the clinical data, and concluded that the VentrAssist LVAD has met the performance goal in the BTT Trial. Furthermore, adverse event rates were reviewed by the DSMB, and were felt to be consistent with the published rates for similar populations and devices, and markedly improved over first generation pulsatile LVADs. | ||
| Read more | BACK TO TOP |
| |
| ||
| ||
|
|
NSW Clinical Trials Business Development Centre
Your Research Connection  The NSW Clinical Trials Business Development Centre (NSW)has been established, through support from OSMR, to support researchers and industry with the conduct of their clinical trials. | ||
| Read more | BACK TO TOP |
| |
WEBSITE | PH: +61 2 9338 6968 | EMAIL
GPO Box 5477, Sydney NSW 2001 AUSTRALIA
Privacy: Any personal information provided to the Department is voluntary and protected by the Privacy and Personal Information Protection Act 1998 (NSW) and the Health Records and Information Privacy Act 2002 (NSW). The Department does not condone the sending of unsolicited commercial electronic messages as defined by the Spam Act 2003 (Cth.). Please refer to our privacy and spam policy for more information and your rights to access and correct the information held.
Disclaimer: This e-newsletter contains information including data, documents and images prepared by the New South Wales Department of Industry & Investment (I&I NSW). While the information has been formulated with all due care, I&I NSW does not warrant or represent that the information is complete, accurate or up to date. The information is subject to change without notice.